# TruAlt Bioenergy share price today (TruAlt Bioenergy Ltd, NSE: TRUALT)

> TruAlt Bioenergy share price today: ₹359.65 at the NSE close on 3 November 2026, down 19.4% in a year. TruAlt Bioenergy (NSE: TRUALT) is worth ₹3,081 crore, trades at a P/E of 13.5 and has closed between ₹319.65 and ₹531.95 over the past 52 weeks. > TruAlt Bioenergy Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TRUALT · Miscellaneous · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/trualt-bioenergy-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹359.65 (−19.4% in a year)
- P/E: 13.5× (lower than 100% of the last 1 year)
- Revenue (Sep 2026): ₹811 Cr (+605.2% on a year ago)
- Profit (Sep 2026): ₹35.0 Cr
- Operating margin: 12.0% (+16.0 points on a year ago)
- ROCE: 10%, FY26
- ROIC: 9.1%, against a 12.0% cost of capital: −2.9 points
- Profit that came in as cash: 29%, last 3 years

The main question: profits are rising, but only 29% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the TruAlt Bioenergy share price today? TruAlt Bioenergy Ltd's share price was ₹359.65 at the close on 3 November 2026. It has been falling for 10 weeks. That is 19.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹320 and ₹532, and at that close it sat 19% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 1 year the share price moved −32% while the NIFTY 500 moved −5%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at TruAlt Bioenergy this quarter? One change stood out: operating margin up 16 points on a year earlier. 1. Operating margin up 16 points on a year earlier 12% in the September 2026 quarter, from -4%. ## What are TruAlt Bioenergy's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), TruAlt Bioenergy reported revenue of ₹811 crore, up 605.2% from ₹115 crore a year earlier, and a profit of ₹35.0 crore, against a loss of ₹38.0 crore a year earlier. ### TruAlt Bioenergy results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹811 crore | ₹115 crore | +605.2% |
| Profit | ₹35.0 crore | loss of ₹38.0 crore | n/a |
| Earnings per share | ₹4.04 | ₹−4.42 | n/a |
| Operating margin | 12.0% | −4.0% | +16.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). TruAlt Bioenergy's management discussed these results on a call held on 26 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the TruAlt Bioenergy share price history? TruAlt Bioenergy closed at ₹359.65 on 3 November 2026, down 19.4% from ₹446.10 a year earlier (31 October 2025). Its highest weekly close since October 2025 was ₹531.95 on 9 June 2026. ### TruAlt Bioenergy share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹406.70 | −11.6% |
| 1 month ago · 1 Oct 2026 | ₹444.30 | −19.1% |
| 6 months ago · 30 Apr 2026 | ₹492.45 | −27.0% |
| 1 year ago · 31 Oct 2025 | ₹446.10 | −19.4% |
| Earliest weekly close in our records · 3 Oct 2025 | ₹530.95 | −32.3% |
| Highest weekly close since October 2025, also the 52-week high · 9 Jun 2026 | ₹531.95 | −32.4% |
| Lowest weekly close since October 2025, also the 52-week low · 23 Jan 2026 | ₹319.65 | +12.5% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (64 weekly closes from 3 October 2025 to 3 November 2026.)

## What is the latest news on TruAlt Bioenergy? 3 Nov 2026: TruAlt Bioenergy closed at ₹359.65, down 11.6% on the week and down 19.1% on the month. 26 Oct 2026: TruAlt Bioenergy held its results call for July to September 2026. Management guided: Average ethanol utilization planned at 75-80% going forward. ### Earlier

- Results for July to September 2026: Revenue up 605.2% on a year earlier. ## What dividend does TruAlt Bioenergy pay? TruAlt Bioenergy has paid no dividend on the NSE since its first NSE close in our records (3 October 2025), the start of the period we checked. No. TruAlt Bioenergy Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did TruAlt Bioenergy management say on the latest results call? On the call for July to September 2026, held on 26 October 2026, TruAlt Bioenergy's management guided: Average ethanol utilization planned at 75-80% going forward. > “We have already received an incentive of approximately 150 crores as viability gap funding under the PM JI-VAN Yojana for the proposed plant.”
> Vijay Nirani, on the call for July to September 2026

### What management guided

- Ethanol volume: 8.5 crore litres cited in hand, later 4.5 crore still due; 6-7 crore more expected in Nov-Dec; ESY26-27 allocation at least 40-42 crore litres versus approximately 66 crore eligible; first figures unreconciled. - FY27 blended ethanol realization estimated at ₹64-65/litre versus ₹67 in prior years; average operating margin may be 1-2% below achieved levels. - Two further Sumitomo plants expected this quarter, taking CBG capacity to approximately 72 TPD; construction planned for six GAIL units. - CBG pipeline visibility of 250 TPD; revenue approximately ₹20 crore over the next two quarters and operating margin expected at 50-55%. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/58283/Conference Call/CC-Oct26.pdf). (From the call for July to September 2026, 26 October 2026.)

## What to watch in TruAlt Bioenergy's next results? When TruAlt Bioenergy reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Check whether pending ethanol supply clears and fresh OMC allocations translate into lifting rather than inventory accumulation. - What to check (from the call)
- Check whether pending ethanol supply clears and fresh OMC allocations translate into lifting rather than inventory accumulation. - Test Q3/Q4 ethanol margin recovery against maize costs, procurement discipline and tender realization. - Track Sumitomo commissioning and CBG ramp-up, including whether planned subsidy and GAIL debt draw materialize. - Look for release of the blending roadmap and a SAF construction decision. ## Which stock lists is TruAlt Bioenergy on? TruAlt Bioenergy is not on any of our India lists this week. ## Is TruAlt Bioenergy profitable? TruAlt Bioenergy Ltd earned ₹35.0 Cr of net profit in the Sep 2026 quarter. Full-year FY26 profit was ₹97.0 Cr. Over 3 years profit has grown 40.5% a year on average. That is 4.3% of the quarter's revenue. The same quarter a year earlier lost ₹38.0 Cr. 3 of the last 10 reported quarters were loss-making. For the full year, FY26 profit was ₹97.0 Cr (−34.0% on the year before). On average over the last four quarters, profit changed +344.5% and revenue +187.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does TruAlt Bioenergy make, and is it growing? TruAlt Bioenergy Ltd reported ₹811 Cr of revenue in the Sep 2026 quarter, +605.2% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 31.4% a year on average. The last full year, FY26, came in at ₹1,728 Cr. The last four reported quarters add to ₹2,747 Cr. FY26 revenue was ₹1,728 Cr, −9.4% on the year before. Recent pace: the last four quarters grew +187.3% on average, against 31.4% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every ₹100 of sales does TruAlt Bioenergy keep? TruAlt Bioenergy Ltd's operating margin was 12.0% in the Sep 2026 quarter, 16.0 percentage points higher than the same quarter a year ago. Across 4 years it has been between 14.0% and 17.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed +16.4 percentage points on the year while gross margin changed +4.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is TruAlt Bioenergy's profit turning into cash? Over the last 3 years, 29% of TruAlt Bioenergy Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used ₹296 Cr of cash, against ₹97.0 Cr of profit. After ₹510 Cr of spending on assets, free cash was −₹806 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 29% of profit came in as cash: the cash cycle got 242 days longer between FY23 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 242 days longer. The next section looks at where the cash is stuck. ## Where does TruAlt Bioenergy's cash go? TruAlt Bioenergy Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 170 days in FY26, up from −72 days in FY23. It spent ₹1,151 Cr on assets over the last 3 years. Customers take 86 days to pay, and stock sits for 173 days on average. At FY26 sales of ₹1,728 Cr, each day of that cycle ties up about ₹4.7 Cr, so roughly ₹805 Cr is tied up in the business at any time. FY26: customers took 86 days to pay and stock sat for 173 days, about 5.7 months of sales sitting as stock, for a full cycle of 170 days, longer than FY23's −72. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 173 days. Customers pay about 86 days after that. Suppliers are paid at 89 days. Together that makes the 170-day cycle. Spending on assets: ₹1,151 Cr over the last 3 years, against ₹210 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹68.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is TruAlt Bioenergy's P/E ratio, and how does it compare with its own history? TruAlt Bioenergy Ltd's P/E is 13.5×, about the lowest it has ever been. Its usual P/E (the middle reading) is 24.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −46.1% while the price moved −19.4%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the TruAlt Bioenergy business getting better or worse? TruAlt Bioenergy Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does TruAlt Bioenergy earn on its capital? TruAlt Bioenergy Ltd earned a ROCE of 10% in FY26. Its return on capital used (ROIC) is 2.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 5.6% net margin and 0.46× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 5.6% net margin × 0.46× asset turnover × 2.48× leverage (assets divided by equity) ≈ 6.4% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 9.1% − 12.0% = −2.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 9.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 5.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does TruAlt Bioenergy have too much debt? TruAlt Bioenergy Ltd has total debt of ₹1,663 Cr against shareholder equity of ₹1,687 Cr as of Sep 2026, so its debt is 0.99× its equity. Year by year, that ratio went from 2.02 in FY25 to 1.05 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the TruAlt Bioenergy shareholding pattern? No group of TruAlt Bioenergy Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is TruAlt Bioenergy from balance-sheet trouble? For TruAlt Bioenergy Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does TruAlt Bioenergy rank in its industry? 53.4 out of 100, rank 11 of 40 in Miscellaneous, with 68% of the evidence available. TruAlt Bioenergy Ltd scores 53.4 out of 100 against the 40 companies it is compared with in Miscellaneous, ranking 11. Earnings are strong; relative strength in its sector is -12.8% and the one-year return is -19.4%. The four parts add up to the total exactly: 25.7 + 10.1 + 11.1 + 6.5 = 53.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is TruAlt Bioenergy compared with? TruAlt Bioenergy ranks 11 of 40 Miscellaneous companies on the 4-Factor Sector Score, with 53.4 out of 100. 1. [Global Education Ltd](https://www.sectoralpha.in/stocks/global-education-ltd) GLOBAL · breaking out · Most evidence points up · 89% evidence 71.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.1/35 · Revenue 28.2% · Profit 3.3% · Operating margin change 0.3 points · 88% evidence Capital efficiency 21.3/25 · ROCE 29.2% · Operating margin 41% · 100% evidence Valuation 14.4/20 · P/E 28.1× · PEG 0.67 · 65% evidence Relative strength 19.9/20 · Lead over its industry 45% · Lead over NIFTY 500 44.6% · 1 year 103.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.1 + 21.3 + 14.4 + 19.9 = 71.7 · What this means: Relative strength against the index is 44.6%, and revenue and profit growth are weak. 2. [Sagility Ltd](https://www.sectoralpha.in/stocks/sagility-ltd) SAGILITY · losing its lead · Most evidence points up · 78% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 28.5% · Profit 28.4% · Operating margin change 0 points · 100% evidence Capital efficiency 17.4/25 · ROCE 13.4% · Operating margin 25% · 100% evidence Valuation 15.6/20 · P/E 18.6× · PEG 0.37 · 65% evidence Relative strength 9.6/20 · Lead over its industry n/a · Lead over NIFTY 500 -1.3% · 1 year -19.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 23.6 + 17.4 + 15.6 + 9.6 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Gulshan Polyols Ltd](https://www.sectoralpha.in/stocks/gulshan-polyols-ltd) GULPOLY · quiet · Evidence leans up · 96% evidence 64.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.2/35 · Revenue 9.4% · Profit 100% · Operating margin change 7 points · 88% evidence Capital efficiency 19.4/25 · ROCE 18.6% · Operating margin 13% · 100% evidence Valuation 14.6/20 · P/E 6× · PEG 1.48 · 100% evidence Relative strength 4.4/20 · Lead over its industry -10.5% · Lead over NIFTY 500 -10.4% · 1 year -5.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 26.2 + 19.4 + 14.6 + 4.4 = 64.6 · What this means: Earnings are strong; relative strength in its sector is -10.5% and the one-year return is -5.9%. 4. [Shree Vasu Logistics Ltd](https://www.sectoralpha.in/stocks/shree-vasu-logistics-ltd) SVLL · leader · Evidence leans up · 64% evidence 62.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.4/35 · Revenue 47.4% · Profit 100% · Operating margin change 0.8 points · 88% evidence Capital efficiency 18.6/25 · ROCE 20.5% · Operating margin 25.8% · 100% evidence Valuation 8.9/20 · P/E 119× · PEG n/a · 15% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 14% · 1 year -0.9% · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.4 + 18.6 + 8.9 + 11.8 = 62.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [R K Swamy Ltd](https://www.sectoralpha.in/stocks/r-k-swamy-ltd) RKSWAMY · Evidence leans up · 69% evidence 62.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/43.75 · Revenue 14.3% · Profit 17.3% · Operating margin change 2.6 points · 88% evidence Capital efficiency 19.5/31.25 · ROCE 12.3% · Operating margin 10.4% · 100% evidence Valuation 17.0/25 · P/E 19.5× · PEG 0.77 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 26 + 19.5 + 17 = 62.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 6. [Aeroflex Enterprises Ltd](https://www.sectoralpha.in/stocks/aeroflex-enterprises-ltd) AEROENTER · turning · Evidence leans up · 71% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.2/35 · Revenue 27.5% · Profit 100% · Operating margin change -5 points · 83% evidence Capital efficiency 13.6/25 · ROCE 12.6% · Operating margin 9% · 76% evidence Valuation 11.4/20 · P/E 9.3× · PEG n/a · 15% evidence Relative strength 17.4/20 · Lead over its industry 28.1% · Lead over NIFTY 500 27.6% · 1 year 43.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 19.2 + 13.6 + 11.4 + 17.4 = 61.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Blue Water Logistics Ltd](https://www.sectoralpha.in/stocks/blue-water-logistics-ltd) BLUEWATER · Evidence leans up · 64% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 163.3% · Profit 169.2% · Operating margin change -2 points · 88% evidence Capital efficiency 17.1/25 · ROCE 31.4% · Operating margin 11% · 100% evidence Valuation 10.8/20 · P/E 15.4× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.1% · 1 year n/a · 25% evidence Exact sum: 20.4 + 17.1 + 10.8 + 12.5 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Anlon Technology Solutions Ltd](https://www.sectoralpha.in/stocks/anlon-technology-solutions-ltd) ANLON · breaking out · Too little evidence to rank firmly · 54% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 100% · Profit 100% · Operating margin change 1 points · 28% evidence Capital efficiency 18.6/25 · ROCE 27.1% · Operating margin 20% · 75% evidence Valuation 7.0/20 · P/E 36× · PEG 1.51 · 100% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 31.2% · 1 year n/a · 25% evidence · 5 of 5 weeks ahead Exact sum: 21 + 18.6 + 7 + 12.2 = 58.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Eveready Industries India Ltd](https://www.sectoralpha.in/stocks/eveready-industries-india-ltd) EVEREADY · basing · Evidence leans up · 66% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 9.8% · Profit 100% · Operating margin change -1 points · 74% evidence Capital efficiency 15.6/25 · ROCE 17.2% · Operating margin 12% · 100% evidence Valuation 11.6/20 · P/E 12.9× · PEG n/a · 50% evidence Relative strength 10.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.8% · 1 year -18% · 25% evidence · 3 of 12 weeks ahead Exact sum: 19.4 + 15.6 + 11.6 + 10 = 56.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Prozone Realty Ltd](https://www.sectoralpha.in/stocks/prozone-realty-ltd) PROZONER · breaking out · Evidence leans up · 68% evidence 55.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue -9.9% · Profit 100% · Operating margin change 8.2 points · 83% evidence Capital efficiency 7.5/25 · ROCE 6% · Operating margin -35.6% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 17.0/20 · Lead over its industry 4.5% · Lead over NIFTY 500 5.1% · 1 year -26.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21.4 + 7.5 + 10 + 17 = 55.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. TruAlt Bioenergy Ltd this page TRUALT · quiet · Evidence leans up · 68% evidence 53.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 57.8% · Profit 50.6% · Operating margin change 16 points · 74% evidence Capital efficiency 10.1/25 · ROCE 10.4% · Operating margin 12% · 100% evidence Valuation 11.1/20 · P/E 13.5× · PEG n/a · 15% evidence Relative strength 6.5/20 · Lead over its industry -12.8% · Lead over NIFTY 500 -12.6% · 1 year -19.4% · 70% evidence · 1 of 12 weeks ahead Exact sum: 25.7 + 10.1 + 11.1 + 6.5 = 53.4 · What this means: Earnings are strong; relative strength in its sector is -12.8% and the one-year return is -19.4%. 12. [Jindal Photo Ltd](https://www.sectoralpha.in/stocks/jindal-photo-ltd) JINDALPHOT · turning · Evidence leans up · 76% evidence 53.0 out of 100 Growth Capital Valuation Relative
13. [Aegis Vopak Terminals Ltd](https://www.sectoralpha.in/stocks/aegis-vopak-terminals-ltd) AEGISVOPAK · quiet · Evidence leans up · 60% evidence 52.2 out of 100 Growth Capital Valuation Relative
14. [Jai Corp Ltd](https://www.sectoralpha.in/stocks/jai-corp-ltd) JAICORPLTD · basing · Too little evidence to rank firmly · 56% evidence 51.2 out of 100 Growth Capital Valuation Relative
15. [GMR Airports Ltd](https://www.sectoralpha.in/stocks/gmr-airports-ltd) GMRAIRPORT · quiet · Evidence leans down · 83% evidence 49.1 out of 100 Growth Capital Valuation Relative
16. [Parin Enterprises Ltd](https://www.sectoralpha.in/stocks/parin-enterprises-ltd) PARIN · losing its lead · Evidence leans down · 63% evidence 48.3 out of 100 Growth Capital Valuation Relative
17. [Anzen India Energy Yield Plus Trust](https://www.sectoralpha.in/stocks/anzen-india-energy-yield-plus-trust) ANZEN · losing its lead · Too little evidence to rank firmly · 52% evidence 47.5 out of 100 Growth Capital Valuation Relative
18. [TCC Concept Ltd](https://www.sectoralpha.in/stocks/tcc-concept-ltd) TCC · quiet · Evidence leans down · 71% evidence 47.1 out of 100 Growth Capital Valuation Relative
19. [Shipping Corporation of India Land & Assets Ltd](https://www.sectoralpha.in/stocks/shipping-corporation-of-india-land-assets-ltd) SCILAL · basing · Evidence leans down · 90% evidence 45.5 out of 100 Growth Capital Valuation Relative
20. [Aqylon Nexus Ltd](https://www.sectoralpha.in/stocks/aqylon-nexus-ltd) AQYLON · basing · Evidence leans down · 71% evidence 43.5 out of 100 Growth Capital Valuation Relative
21. [Inox Green Energy Services Ltd](https://www.sectoralpha.in/stocks/inox-green-energy-services-ltd) INOXGREEN · quiet · Evidence leans down · 71% evidence 41.1 out of 100 Growth Capital Valuation Relative
22. [Delta Corp Ltd](https://www.sectoralpha.in/stocks/delta-corp-ltd) DELTACORP · breaking out · Evidence leans down · 67% evidence 41.1 out of 100 Growth Capital Valuation Relative
23. [GKW Ltd](https://www.sectoralpha.in/stocks/gkw-ltd) GKWLIMITED · turning · Evidence leans down · 61% evidence 38.5 out of 100 Growth Capital Valuation Relative
24. [Kaveri Seed Company Ltd](https://www.sectoralpha.in/stocks/kaveri-seed-company-ltd) KSCL · basing · Evidence leans down · 76% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [IIRM Holdings India Ltd](https://www.sectoralpha.in/stocks/iirm-holdings-india-ltd) IIRM · quiet · Evidence leans down · 64% evidence 36.8 out of 100 Growth Capital Valuation Relative
26. [Unitech Ltd](https://www.sectoralpha.in/stocks/unitech-ltd) UNITECH · basing · Evidence leans down · 68% evidence 35.6 out of 100 Growth Capital Valuation Relative
27. [Stanley Lifestyles Ltd](https://www.sectoralpha.in/stocks/stanley-lifestyles-ltd) STANLEY · quiet · Most evidence points down · 64% evidence 34.3 out of 100 Growth Capital Valuation Relative
28. [Embassy Developments Ltd](https://www.sectoralpha.in/stocks/embassy-developments-ltd) EMBDL · quiet · Most evidence points down · 61% evidence 27.2 out of 100 Growth Capital Valuation Relative
29. [RattanIndia Enterprises Ltd](https://www.sectoralpha.in/stocks/rattanindia-enterprises-ltd) RTNINDIA · basing · Most evidence points down · 61% evidence 24.8 out of 100 Growth Capital Valuation Relative
30. Exhicon Events Media Solutions Ltd losing its lead · Too little evidence to rank firmly · 42% evidence 58.0 out of 100 Growth Capital Valuation Relative
31. [Central Mine Planning & Design Institute Ltd](https://www.sectoralpha.in/stocks/central-mine-planning-design-institute-ltd) CMPDI · quiet · Too little evidence to rank firmly · 38% evidence 57.3 out of 100 Growth Capital Valuation Relative
32. [Take Ltd](https://www.sectoralpha.in/stocks/take-solutions-ltd) TAKE · Too little evidence to rank firmly · 38% evidence 55.8 out of 100 Growth Capital Valuation Relative
33. [Fabtech Cleanrooms Ltd](https://www.sectoralpha.in/stocks/fabtech-cleanrooms-ltd) breaking out · Too little evidence to rank firmly · 41% evidence 54.8 out of 100 Growth Capital Valuation Relative
34. [Devson Catalyst Ltd](https://www.sectoralpha.in/stocks/devson-catalyst-ltd) Too little evidence to rank firmly · 15% evidence 52.9 out of 100 Growth Capital Valuation Relative
35. [Qualitek Labs Ltd](https://www.sectoralpha.in/stocks/qualitek-labs-ltd) breaking out · Too little evidence to rank firmly · 31% evidence 49.9 out of 100 Growth Capital Valuation Relative
36. [Indiqube Spaces Ltd](https://www.sectoralpha.in/stocks/indiqube-spaces-ltd) INDIQUBE · turning · Too little evidence to rank firmly · 46% evidence 47.7 out of 100 Growth Capital Valuation Relative
37. [Maagh Advertising & Marketing Services Ltd](https://www.sectoralpha.in/stocks/maagh-advertising-marketing-services-ltd) Too little evidence to rank firmly · 21% evidence 47.5 out of 100 Growth Capital Valuation Relative
38. [Lords Mark Industries Limited](https://www.sectoralpha.in/stocks/lords-mark-industries-limited) quiet · Too little evidence to rank firmly · 43% evidence 45.7 out of 100 Growth Capital Valuation Relative
39. [Tandhan Industries Ltd](https://www.sectoralpha.in/stocks/tandhan-industries-ltd) turning · Too little evidence to rank firmly · 37% evidence 42.4 out of 100 Growth Capital Valuation Relative
40. [Shree Rama Newsprint Ltd](https://www.sectoralpha.in/stocks/shree-rama-newsprint-ltd) RAMANEWS · Too little evidence to rank firmly · 48% evidence 32.5 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Miscellaneous](https://www.sectoralpha.in/sectors/miscellaneous), all 40 compared on one page. ## Which companies are close to TruAlt Bioenergy in size? TruAlt Bioenergy is the 11th largest of 40 Miscellaneous companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Kaveri Seed Company, RattanIndia Enterprises and Anzen India Energy Yield Plus Trust. Just below it: Lords Mark Industries, Eveready Industries India and Delta Corp. ### Miscellaneous companies close in size

1. [Kaveri Seed Company Ltd](https://www.sectoralpha.in/stocks/kaveri-seed-company-ltd) ₹3,390 crore
2. [RattanIndia Enterprises Ltd](https://www.sectoralpha.in/stocks/rattanindia-enterprises-ltd) ₹3,261 crore
3. [Anzen India Energy Yield Plus Trust](https://www.sectoralpha.in/stocks/anzen-india-energy-yield-plus-trust) ₹3,171 crore
4. TruAlt Bioenergy Ltd ₹3,084 crore
5. [Lords Mark Industries Limited](https://www.sectoralpha.in/stocks/lords-mark-industries-limited) ₹3,079 crore
6. [Eveready Industries India Ltd](https://www.sectoralpha.in/stocks/eveready-industries-india-ltd) ₹2,257 crore
7. [Delta Corp Ltd](https://www.sectoralpha.in/stocks/delta-corp-ltd) ₹1,986 crore

[All 40 Miscellaneous companies, largest first](https://www.sectoralpha.in/sectors/miscellaneous#all-companies)

### Companies close in size in other industries

1. [Styrenix Performance Materials Ltd](https://www.sectoralpha.in/stocks/styrenix-performance-materials-ltd) ₹3,087 crore · Petrochem - Polymers
2. [Bajaj Electricals Ltd](https://www.sectoralpha.in/stocks/bajaj-electricals-ltd) ₹3,085 crore · Domestic Appliances
3. TruAlt Bioenergy Ltd ₹3,084 crore
4. [Lords Mark Industries Limited](https://www.sectoralpha.in/stocks/lords-mark-industries-limited) ₹3,079 crore · Miscellaneous
5. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) ₹3,070 crore · Pharma - API & CRAMS

## What else do people ask about TruAlt Bioenergy? ### What is TruAlt Bioenergy's share price today? TruAlt Bioenergy Ltd's share price is ₹359.65, −19.4% over the past year. The whole company is worth ₹3,081 Cr on the market. In the last 52 weeks it traded between ₹320 to ₹532; today it is 19% of the way up from the low, 19.1% below its 200-day average (as of 3 November 2026). ### What were TruAlt Bioenergy's latest quarterly results? TruAlt Bioenergy Ltd reported revenue of ₹811 Cr and net profit of ₹35.0 Cr for the Sep 2026 quarter. Earnings per share were ₹4.04. The operating margin was 12.0%, 16.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is TruAlt Bioenergy's market cap? TruAlt Bioenergy Ltd's market capitalisation is ₹3,081 Cr at a share price of ₹359.65. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is TruAlt Bioenergy performing? TruAlt Bioenergy Ltd's share price has been falling for 10 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will TruAlt Bioenergy's share price go up? This page does not forecast TruAlt Bioenergy Ltd's share price. What it shows instead: the share price is ₹359.65, and it has been falling for 10 weeks. Its P/E of 13.5× is higher than 0% of its own last 1 years (as of 3 November 2026). ### Who owns TruAlt Bioenergy? Promoters own 71.4% of TruAlt Bioenergy Ltd, foreign institutions 0.6%, domestic institutions 9.1% and the public 18.9% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Does TruAlt Bioenergy have too much debt? Yes, TruAlt Bioenergy Ltd has a lot of debt: its debt is 1.09× its equity, and its operating profit is 2 times its interest bill. FY26 borrowings were ₹1,652 Cr against equity of ₹1,521 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is TruAlt Bioenergy in its business cycle? TruAlt Bioenergy Ltd's FY26 operating margin was 17.0%, against a 4-year range of 14.0% to 17.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 12.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the TruAlt Bioenergy story? The main question: profits are rising, but only 29% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is TruAlt Bioenergy a stock worth studying right now? What the numbers show: TruAlt Bioenergy Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a TruAlt Bioenergy share price forecast for 2026? What management itself guided: Average ethanol utilization planned at 75-80% going forward. This is research, not advice. We’re not SEBI-registered.